卵巢癌中紫杉醇耐药性研究进展

doi:10.11904/j.issn.1002-3070.2025.04.013

摘要/Abstract

摘要： 在妇科恶性肿瘤中,卵巢癌死亡率最高。目前针对卵巢癌的化疗药物主要以铂类和紫杉烷类药物为主。紫杉醇是一种紫杉烷类药物,是使用最广泛的化疗药物之一,也是治疗卵巢癌的一线化疗药物。尽管紫杉醇已被广泛用于卵巢癌治疗,但耐药性的产生限制了其临床疗效。本文阐述卵巢癌中紫杉醇耐药机制及治疗策略,包括联合用药、新靶点探索、新型载体结合等治疗方式,为解决紫杉醇在卵巢癌治疗过程中的耐药问题提供依据。

关键词: 紫杉醇, 卵巢癌, 耐药性, 治疗策略

Abstract: Ovarian cancer has the highest mortality among all gynecological tumors.Currently,platinum and taxanes based chemotherapy drugs are mainly used for ovarian cancer.Paclitaxel is a taxane drug,one of the most widely used chemotherapy drugs,and also a first-line chemotherapeutic drug for treating ovarian cancer.Despite its widespread use in the treatment of ovarian cancer,paclitaxel′s clinical has efficacy is hindered by the development of resistance.This article mainly discusses the mechanism and treatment strategies of paclitaxel resistance in ovarian cancer,including combination therapy,exploration of new targets,and the combination of novel carriers,providing a basis for solving the problem of paclitaxel resistance in the treatment of ovarian cancer.

Key words: Paclitaxel, Ovarian cancer, Drug resistance, Treatment strategies

中图分类号:

R737.31

吴小帆, 李琳. 卵巢癌中紫杉醇耐药性研究进展[J]. 实用肿瘤学杂志, 2025, 39(4): 343-347.

WU Xiaofan, LI Lin. Research progress on paclitaxel resistance in ovarian cancer[J]. Journal of Practical Oncology, 2025, 39(4): 343-347.

参考文献

1 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
2 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
3 Marupudi NI,Han JE,Li KW,et al.Paclitaxel:a review of adverse toxicities and novel delivery strategies[J].Expert Opin Drug Saf,2007,6(5):609-621.
4 Wanderley CW,Colón DF,Luiz JPM,et al.Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner[J].Cancer Res,2018,78(20):5891-5900.
5 Lau TS,Chan LKY,Man GCW,et al.Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis[J].Cancer Immunol Res,2020,8(8):1099-1111.
6 Vaidyanathan A,Sawers L,Gannon AL,et al.ABCB1(MDR1)induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells[J].Br J Cancer,2016,115(4):431-441.
7 Feng Q,Li X,Sun W,et al.Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1[J].Biochem Pharmacol,2020,178:114092.
8 Lin TY,Gu SY,Lin YH,et al.Paclitaxel-resistance facilitates glycolytic metabolism via Hexokinase-2-regulated ABC and SLC transporter genes in ovarian clear cell carcinoma[J].Biomed Pharmacother,2024,180:117452.
9 Park DC,Yeo SG,Wilson MR,et al.Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer[J].Neoplasia,2008,10(9):964-972.
10 Giannakakou P,Sackett DL,Kang YK,et al.Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization[J].J Biol Chem,1997,272(27):17118-17125.
11 Mooneyham A,Iizuka Y,Yang Q,et al.UNC-45A is a novel microtubule-associated protein and regulator of paclitaxel sensitivity in ovarian cancer cells[J].Mol Cancer Res,2019,17(2):370-383.
12 Nan G,Zhao SH,Wang T,et al.CD147 supports paclitaxel resistance via interacting with RanBP1[J].Oncogene,2022,41(7):983-996.
13 Yang YI,Wang YY,Ahn JH,et al.CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment[J].Biomed Pharmacother,2022,153:113474.
14 Kohli A,Huang SL,Chang TC,et al.H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor[J].Cancer Sci,2022,113(8):2616-2626.
15 Zhang SF,Wang XY,Fu ZQ,et al.TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer[J].Autophagy,2015,11(2):225-238.
16 Xu H,Zeng S,Wang Y,et al.Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells[J].J Pathol,2023,261(2):210-226.
17 Wu X,Zhao J,Ruan Y,et al.Sialyltransferase ST3GAL1 promotes cell migration,invasion,and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer[J].Cell Death Dis,2018,9(11):1102.
18 Yu Z,Wang Y,Wang B,et al.Metformin affects paclitaxel sensitivity of ovarian cancer cells through autophagy mediated by long noncoding RNASNHG7/miR-3127-5p axis[J].Cancer Biother Radiopharm,2022,37(9):792-801.
19 Kim JS,Shin MJ,Lee SY,et al.BBT-877,a novel autotaxin inhibitor,abrogates drug resistance in epithelial ovarian cancer stem cells[J].Anticancer Res,2024,44(3):1131-1142.
20 Lacroix A,Farhat R,Robert A,et al.The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models[J].Front Pharmacol,2024,15:1444973.
21 Kong QW,Yang J,Li D,et al.Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo[J].J Ethnopharmacol,2023,300:115728.
22 Huang SL,Chang TC,Sun NK.Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity[J].Biochem Pharmacol,2023,212:115581.
23 Yang J,Li N,Zhao X,et al.WP1066,a small molecule inhibitor of STAT3,chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin[J].Biochem Pharmacol,2024,221:116040.
24 Moisan F,Francisco EB,Brozovic A,et al.Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers[J].Mol Oncol,2014,8(7):1231-1239.
25 Li X,Guan W,Liu H,et al.Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer[J].Apoptosis,2024,29(9-10):1546-1563.
26 Lim YJ,Kim HS,Bae S,et al.Pan-EGFR inhibitor dacomitinib resensitizes paclitaxel and induces apoptosis via elevating intracellular ROS levels in ovarian cancer SKOV3-TR cells[J].Molecules,2024,29(1):274.
27 Bae S,Bae S,Kim HS,et al.Deguelin restores paclitaxel sensitivity in paclitaxel-resistant ovarian cancer cells via inhibition of the EGFR signaling pathway[J].Cancer Manag Res,2024,16:507-525.
28 Wu D,Liu J,Yang X,et al.ANGPTL3 diminishes the resistance of ovarian cancer to paclitaxel by blocking the PI3K-Akt-mTOR signaling pathway[J].Heliyon,2024,10(11):e31520.
29 Gelderblom H,Verweij J,Nooter K,et al.Cremophor EL:the drawbacks and advantages of vehicle selection for drug formulation[J].Eur J Cancer,2001,37(13):1590-1598.
30 Wu Y,Yang Y,Lv X,et al.Nanoparticle-based combination therapy for ovarian cancer[J].Int J Nanomedicine,2023,18:1965-1987.
31 Wang L,Li S,Zhu D,et al.Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer:a retrospective study[J].J Gynecol Oncol,2023,34(4):e44.
32 Cheng C,Jiang W,Luo Y,et al.NIR activated multimodal therapeutics based on metal-phenolic networks-functionalized nanoplatform for combating against multidrug resistance and metastasis[J].Small,2023,19(14):e2206174.
33 Korzun T,Moses AS,Kim J,et al.Nanoparticle-based follistatin messenger RNA therapy for reprogramming metastatic ovarian cancer and ameliorating cancer-associated cachexia[J].Small,2022,18(44):e2204436.
34 Lai MH,Lin WJ.Zein-PEG nanoparticles modified with hyaluronic acid for paclitaxel delivery in SKOV3 ovarian cancer cells[J].Int J Biol Macromol,2024,281(Pt 4):136651.
35 Gaikwad NM,Chaudhari PD,Shaikh KS,et al.Dual drug-loaded polymeric mixed micelles for ovarian cancer:Approach to enhanced therapeutic efficacy of albendazole and paclitaxel[J].J Cell Mol Med,2024,28(11):e18389.

[1]	代风雪, 王振飞. 硫化氢在胃癌治疗中的潜在作用及研究进展[J]. 实用肿瘤学杂志, 2025, 39(4): 330-337.
[2]	苏少飞, 张恩婕, 刘建辉, 高燕. 基于孟德尔随机化探究20种代谢产物与卵巢癌发病风险的因果关联[J]. 实用肿瘤学杂志, 2025, 39(3): 191-200.
[3]	寇帅, 王榆平, 孙小霞, 任娟娟. 基于年龄-时期-队列模型的1992—2021年中国卵巢癌发病和死亡分析[J]. 实用肿瘤学杂志, 2025, 39(1): 7-12.
[4]	张华, 努尔比亚·依比布拉, 路鹏霏, 贾春丽, 裴轩萱, 包永星. CXCL8对宫颈癌细胞紫杉醇敏感性的影响及机制研究[J]. 实用肿瘤学杂志, 2025, 39(1): 13-20.
[5]	孙莉君, 董大伟. 基于铂类耐药相关基因的卵巢癌分型和预后研究[J]. 实用肿瘤学杂志, 2024, 38(3): 184-191.
[6]	高燕, 韩晓阳, 程瑾, 侯丽莎, 岳文涛. 单细胞转录组数据揭示PHLDA1是卵巢癌T细胞耗竭的关键分子[J]. 实用肿瘤学杂志, 2024, 38(2): 79-87.
[7]	高燕, 姚盟成, 李哲丰, 韩晓阳, 岳文涛. 单细胞测序数据揭示DMKN在卵巢癌中的诊断及预测价值[J]. 实用肿瘤学杂志, 2023, 37(6): 478-484.
[8]	樊婷婷, 丁丹妮, 赵子雪, 于洋, 韩凤娟. 脂肪酸代谢与卵巢癌[J]. 实用肿瘤学杂志, 2023, 37(5): 429-433.
[9]	冯诚天, 黄芙蓉, 姜永冬. 脂质代谢与乳腺癌曲妥珠单抗耐药性机制的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 155-159.
[10]	孙阜圣, 徐冶, 张永健, 娄阁. 卵巢癌类器官模型的研究进展和治疗新策略[J]. 实用肿瘤学杂志, 2022, 36(4): 346-350.
[11]	胡宗涛, 刘演, 高世乐, 甘晨, 张永康. 高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价[J]. 实用肿瘤学杂志, 2022, 36(2): 144-149.
[12]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.
[13]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[14]	张文文,姜亮亮(综述),王晶(审校). CAR-T疗法在卵巢癌中的应用前景[J]. 实用肿瘤学杂志, 2021, 35(1): 59-63.
[15]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.